Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
BioMarin Pharmaceutical Inc. - Common Stock
(NQ:
BMRN
)
60.72
+0.73 (+1.22%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 4, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about BioMarin Pharmaceutical Inc. - Common Stock
< Previous
1
2
...
8
9
10
11
12
13
14
15
16
...
18
19
Next >
uniQure Stock Trying To Close In On Key Technical Measure
↗
February 28, 2023
uniQure stock had its Relative Strength Rating upgraded to 79 Tuesday -- a nice improvement, but still shy of the 80-plus desired score.
Via
Investor's Business Daily
BioMarin Hints Probable Delay For US Approval For Roctavian, But Analyst Convinced For Transformative 2023
↗
February 28, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 22, 2023
↗
February 22, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 21, 2023
↗
February 21, 2023
Via
Benzinga
BioMarin Valuation Fair, But Expectations From Hemophilia Therapy Too High, Says Analyst
↗
January 30, 2023
Via
Benzinga
Earnings Scheduled For February 27, 2023
↗
February 27, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.14 per share on revenue of $505.61 million.
Via
Benzinga
Preview: Biomarin Pharmaceutical's Earnings
↗
February 24, 2023
Via
Benzinga
Analyst Ratings for Biomarin Pharmaceutical
↗
February 22, 2023
Via
Benzinga
3 Prime Healthcare Takeover Targets
↗
February 14, 2023
These three companies are attractive targets for their potential.
Via
The Motley Fool
Moderna Stock Getting Closer To Key Technical Benchmark
↗
February 10, 2023
On Friday, biotech Moderna stock received an upgrade to its Relative Strength (RS) Rating, to 72 from 69 a day earlier.
Via
Investor's Business Daily
BioRestorative (NASDAQ: BRTX) Ramps Up Production In Anticipation Of Positive Phase 2 Results
↗
February 03, 2023
Chronic lumbar disc disease (cLDD) is a debilitating condition affecting millions of people worldwide. It is characterized by back pain, stiffness, and restricted movement due to damage to the bony...
Via
Benzinga
What 5 Analyst Ratings Have To Say About Biomarin Pharmaceutical
↗
January 30, 2023
Via
Benzinga
3 Drug Stocks With Promising Pipelines for 2023
↗
January 23, 2023
These 3 drug stocks with promising pipelines are in position to reward investors in 2023 due to multiple factors.
Via
InvestorPlace
Cramer Is Holding This Biotech Stock
↗
January 12, 2023
On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended holding Biomarin Pharmaceutical Inc (NASDAQ: BMRN).
Via
Benzinga
6 Analysts Have This to Say About Biomarin Pharmaceutical
↗
January 11, 2023
Via
Benzinga
2 Top Biotech Stocks Defying the Bear Market
↗
January 10, 2023
Some stocks are hitting new highs.
Via
The Motley Fool
Expert Ratings for Biomarin Pharmaceutical
↗
November 29, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023
↗
January 30, 2023
Via
Benzinga
Vertex Pharmaceuticals Stock Sees Rising Relative Strength
↗
January 11, 2023
A Relative Strength Rating upgrade for Vertex Pharmaceuticals shows improving technical performance. Will it continue?
Via
Investor's Business Daily
BioMarin's Growth Prospects Soar with Potential Voxzogo and Roctavian Launches, Analyst Raises Price Target
↗
January 11, 2023
Via
Benzinga
Expert Ratings for Biomarin Pharmaceutical
↗
October 31, 2022
Within the last quarter, Biomarin Pharmaceutical (NASDAQ:BMRN) has observed the following analyst ratings:
Via
Benzinga
Top Picks For 2023: Catalyst Pharmaceuticals
↗
January 02, 2023
Catalyst Pharmaceuticals is a small-cap biopharma company focused on in-licensing, developing, and commercializing novel medicines to treat rare diseases. Let's take a closer look to see why it's a top...
Via
Talk Markets
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
December 01, 2022
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
↗
December 01, 2022
Good morning! We're starting off Thursday with a breakdown of the biggest pre-market stock movers traders need to know about!
Via
InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
↗
November 29, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Canceled AdCom, UniQure's Hemgenix Approval Show Positive Signs For BioMarin's Hemophilia Candidate
↗
November 23, 2022
Via
Benzinga
The FDA Just Approved The Most Expensive Drug Ever — Sending UniQure Stock On A Warpath
↗
November 23, 2022
And shares of its developer are on a warpath this week.
Via
Investor's Business Daily
Why Biomarin Pharmaceutical Stock Hit A New 52-Week High Today
↗
November 23, 2022
Biomarin Pharmaceutical Inc (NASDAQ: BMRN) shares are trading higher by 6.97% to $97.54 Wednesday morning after the company announced advancements in the FDA review of ROCTAVIAN for adults with severe...
Via
Benzinga
$1.4 Million Bet On This Real Estate Stock? 3 Stocks Insiders Are Buying
↗
November 03, 2022
Although US stocks closed lower on Wednesday, there were a few notable insider trades.
Via
Benzinga
10 Analysts Have This to Say About Biomarin Pharmaceutical
↗
October 31, 2022
Over the past 3 months, 10 analysts have published their opinion on Biomarin Pharmaceutical (NASDAQ:BMRN) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
< Previous
1
2
...
8
9
10
11
12
13
14
15
16
...
18
19
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
